| Literature DB >> 33806359 |
Nicole Naumann1, Johannes Lübke1, Sofie Baumann1, Juliana Schwaab1, Oliver Hoffmann1, Sebastian Kreil1, Vito Dangelo1, Lukas Reiter1, Peter Bugert2, Thomas Kristensen3,4, Karl Sotlar5, Verena Haselmann6, Sven Schneider6, Georgia Metzgeroth1, Christel Weiss7, Henning D Popp1, Alice Fabarius1, Wolf-Karsten Hofmann1, Nicholas C P Cross8,9, Andreas Reiter1, Mohamad Jawhar1.
Abstract
In systemic mastocytosis (SM), qualitative and serial quantitative assessment of the KIT D816V mutation is of diagnostic and prognostic relevance. We investigated peripheral blood and bone marrow samples of 161 patients (indolent SM (ISM), n = 40; advanced SM, AdvSM, n = 121) at referral and during follow-up for the KIT D816V variant allele frequency (VAF) at the DNA-level and the KIT D816V expressed allele burden (EAB) at the RNA-level. A round robin test with four participating laboratories revealed an excellent correlation (r > 0.99, R2 > 0.98) between three different DNA-assays. VAF and EAB strongly correlated in ISM (r = 0.91, coefficient of determination, R2 = 0.84) but only to a lesser extent in AdvSM (r = 0.71; R2 = 0.5). However, as compared to an EAB/VAF ratio ≤2 (cohort A, 77/121 patients, 64%) receiver operating characteristic (ROC) analysis identified an EAB/VAF ratio of >2 (cohort B, 44/121 patients, 36%) as predictive for an advanced phenotype and a significantly inferior median survival (3.3 vs. 11.7 years; p = 0.005). In terms of overall survival, Cox-regression analysis was only significant for the EAB/VAF ratio >2 (p = 0.006) but not for VAF or EAB individually. This study demonstrates for the first time that the transcriptional activity of KIT D816V may play an important role in the pathophysiology of SM.Entities:
Keywords: KIT D816V; advanced SM; allele burden; survival; variant allele frequency
Mesh:
Substances:
Year: 2021 PMID: 33806359 PMCID: PMC7961551 DOI: 10.3390/ijms22052562
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923